These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 21820392)

  • 1. Safety and immunogenicity of the tetravalent protein-conjugated meningococcal vaccine (MCV4) in recipients of related and unrelated allogeneic hematopoietic stem cell transplantation.
    Mahler MB; Taur Y; Jean R; Kernan NA; Prockop SE; Small TN
    Biol Blood Marrow Transplant; 2012 Jan; 18(1):145-9. PubMed ID: 21820392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of conjugate quadrivalent meningococcal vaccination after hematopoietic cell transplantation.
    Cheng MP; Pandit A; Antin JH; Walsh SR; Huynh D; Ghobrial IM; Baden LR; Marty FM; Issa NC
    Blood Adv; 2018 Jun; 2(11):1272-1276. PubMed ID: 29871892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Tdap upon antibody response to meningococcal polysaccharide when administered before, with or after the quadrivalent meningococcal TT-conjugate vaccine (coadministered with the 13-valent pneumococcal CRM197-conjugate vaccine) in adult Hajj pilgrims: A randomised controlled trial.
    Tashani M; Alfelali M; Barasheed O; Alqahtani AS; Heron L; Wong M; Rashid H; Findlow H; Borrow R; Booy R
    Vaccine; 2018 Jul; 36(29):4375-4382. PubMed ID: 29880243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase 2, Randomized, Active-controlled, Observer-blinded Study to Assess the Immunogenicity, Tolerability and Safety of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered With Tetanus, Diphtheria and Acellular Pertussis Vaccine and Serogroup A, C, Y and W-135 Meningococcal Conjugate Vaccine in Healthy US Adolescents.
    Muse D; Christensen S; Bhuyan P; Absalon J; Eiden JJ; Jones TR; York LJ; Jansen KU; O'Neill RE; Harris SL; Perez JL
    Pediatr Infect Dis J; 2016 Jun; 35(6):673-82. PubMed ID: 26974889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on prevention of meningococcal disease: focus on tetravalent meningococcal conjugate vaccine.
    Mehlhorn AJ; Balcer HE; Sucher BJ
    Ann Pharmacother; 2006 Apr; 40(4):666-73. PubMed ID: 16595570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial.
    Borja-Tabora CF; Montalban C; Memish ZA; Boutriau D; Kolhe D; Miller JM; Van der Wielen M
    BMC Infect Dis; 2015 Oct; 15():409. PubMed ID: 26437712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and Safety of a Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine 6 Years After MenC Priming as Toddlers.
    Nolan T; Booy R; Marshall HS; Richmond P; Nissen M; Ziegler JB; Baine Y; Traskine M; Jastorff A; Van der Wielen M
    Pediatr Infect Dis J; 2019 Jun; 38(6):643-650. PubMed ID: 31116180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents.
    Siberry GK; Williams PL; Lujan-Zilbermann J; Warshaw MG; Spector SA; Decker MD; Heckman BE; Demske EF; Read JS; Jean-Philippe P; Kabat W; Nachman S;
    Pediatr Infect Dis J; 2010 May; 29(5):391-6. PubMed ID: 20431379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharide-diphtheria toxoid conjugate vaccine given to healthy adults.
    Campbell JD; Edelman R; King JC; Papa T; Ryall R; Rennels MB
    J Infect Dis; 2002 Dec; 186(12):1848-51. PubMed ID: 12447774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Sep; 58(37):1042-3. PubMed ID: 19779400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents.
    Gill CJ; Baxter R; Anemona A; Ciavarro G; Dull P
    Hum Vaccin; 2010 Nov; 6(11):881-7. PubMed ID: 21339701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents.
    Jacobson RM; Jackson LA; Reisinger K; Izu A; Odrljin T; Dull PM
    Pediatr Infect Dis J; 2013 Apr; 32(4):e170-7. PubMed ID: 23114372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine.
    Dbaibo G; Van der Wielen M; Reda M; Medlej F; Tabet C; Boutriau D; Sumbul A; Anis S; Miller JM
    Int J Infect Dis; 2012 Aug; 16(8):e608-15. PubMed ID: 22704725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents.
    Quiambao BP; Jain H; Bavdekar A; Dubey AP; Kolhe D; Bianco V; Van der Wielen M; Miller JM
    Hum Vaccin Immunother; 2016 Aug; 12(8):2162-2168. PubMed ID: 27152501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of a meningococcal quadrivalent conjugate vaccine in five- to eight-year-old Saudi Arabian children previously vaccinated with two doses of a meningococcal quadrivalent polysaccharide vaccine.
    Khalil M; Al-Mazrou Y; Findlow H; Chadha H; Bosch Castells V; Johnson DR; Borrow R
    Clin Vaccine Immunol; 2012 Oct; 19(10):1561-6. PubMed ID: 22855388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of a meningococcal quadrivalent conjugate vaccine in Saudi Arabian adolescents previously vaccinated with one dose of bivalent and quadrivalent meningococcal polysaccharide vaccines: a phase III, controlled, randomized, and modified blind-observer study.
    Al-Mazrou Y; Khalil M; Findlow H; Chadha H; Bosch Castells V; Johnson DR; Borrow R
    Clin Vaccine Immunol; 2012 Jul; 19(7):999-1004. PubMed ID: 22552602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Responses in U.S. Military Personnel Who Received Meningococcal Conjugate Vaccine (MenACWY) Concomitantly with Other Vaccines Were Higher than in Personnel Who Received MenACWY Alone.
    Broderick MP; Romero-Steiner S; Rajam G; Johnson SE; Milton A; Kim E; Choi LJ; Radin JM; Schmidt DS; Carlone GM; Messonnier N; Faix DJ
    Clin Vaccine Immunol; 2016 Aug; 23(8):672-80. PubMed ID: 27280619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.
    Snape MD; Perrett KP; Ford KJ; John TM; Pace D; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ
    JAMA; 2008 Jan; 299(2):173-84. PubMed ID: 18182599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of the live attenuated varicella vaccine following T replete or T cell-depleted related and unrelated allogeneic hematopoietic cell transplantation (alloHCT).
    Chou JF; Kernan NA; Prockop S; Heller G; Scaradavou A; Kobos R; Knowles MA; Papadopoulos EB; Casson A; Copeland C; Torok-Castanza J; Zakak N; Ruggiero J; Small TN
    Biol Blood Marrow Transplant; 2011 Nov; 17(11):1708-13. PubMed ID: 21664979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Responses to Booster Vaccination With Meningococcal ABCWY Vaccine After Primary Vaccination With Either Investigational or Licensed Vaccines: A Phase 2 Randomized Study.
    Szenborn L; Block SL; Jackowska T; Konior R; D'Agostino D; Smolenov I; Toneatto D; Welsch JA
    Pediatr Infect Dis J; 2018 May; 37(5):475-482. PubMed ID: 29329168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.